Business
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg
About this update from Arbutus Biopharma Corporation
[{"type":"text","content":"AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after meeting stopping criteria, there has been no evidence of virologic or clinical relapse in 8-24 weeks of follow-up Preliminary data to date have shown that AB-729 remains generally safe and well-tolerated after completing dosing in 41 patients AB-729 continues to restore HBV-specific T-cells and decrease exhausted T-cells AB-836, our oral capsid inhibitor, dosed at 100mg or 200mg once daily for 28 days, achieved mean declines in HBV DNA of 3.04 and 3.55 log10, respectively, however safety findings warrant further evaluation in healthy volunteers AB-101, our oral PD-L1 inhibitor, mediates activation and reinvigoration of HBV-specific T-cells from chronic hepatitis B patients in a pre-clinical model Conference Call and Webcast Scheduled for 8:00 AM ET, Monday, June 27, 2022 WARMINSTER, Pa., June 25, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the presentation of new clinical and pre-clinical data from its proprietary compounds at the European Association for the Study of the Liver (EASL) International Liver Congress™ (ILC). The new clinical data for AB-729, our RNAi therapeutic, continues to support its development as a potential cornerstone agent for the treatment of chronic hepatitis B (cHBV) infection. In addition, when AB-729 and nucleos(t)ide analogues (NA) were discontinued in the first five patients who met stopping criteria and consented, there was no evidence of virologic or clinical relapse in at least 8-24 weeks of follow-up, which may lead to a functional cure. AB-836, our oral capsid inhibitor, demonstrated robust antiviral activity, however, two patients in the 200 mg cohort experienced alanine aminotransferase (ALT) elevations. Based on these observations along with potentially correlated immunological findings, we plan to conduct a Phase 1 clinical trial in healthy volunteers before progressing this program. William Collier, Presid...